Life Sciences Archive » August, 2017

Life Sciences - August, 2017

367 articles

• Ex-Pharma Accountant, 2 Others Admit To Insider Trading
• Unclear Grammar Lands AbbVie-Novartis IP Row In Arbitration
• Fed. Circ. Won't Rehear Ax Of Cleveland Clinic Test Patent
• PhRMA Joins Fray In Gilead's 9th Circ. FCA Battle
• Atty Allegedly Caught Stealing Secrets In Medical Device Co.
• Impax Must Pay For GSK Wellbutrin Settlement, Teva Says
• Ariz. AG Sues Insys, Docs Over Fentanyl Spray Marketing
• Mylan, Other Drugmakers Must Pay $67M In Antitrust Suit
• Investigate Gilead Patent Deals, AIDS Activists Urge NY
• Activist Investor Elliott Demands More For Stada Stake
• AbbVie Wins First AndroGel Suit In State Court
• ITC To Probe Microfluidic Chip Imports Accused Of Infringing
• The Psychology Of Hourly Fee Arrangements
• Pfizer, Teva Among Latest Opioid Makers In Mo. Probe
• Pa. Mayor To Sue Pharma Cos. Over Opioid Crisis
• Full Fed. Circ. To Weigh USPTO's Win-Or-Lose Atty Fees Rule
• Uncertainty Remains For Pharma Product Hopping Liability
• Indonesia's Troublesome New Patent Law
• High Court Bristol-Myers Ruling: Direction For State Courts
• Teva Hit With Investor Suit Over $40.5B Actavis Merger
• 4 Fast Facts As FDA Clears 'Historic' Novartis Therapy
• Amarin Calls For ITC Investigation Of Omega-3 Supplements
• FDA Issues Guidance On Real-World Medical Device Data
• Apotex Cleared To Intervene In Eagle's Orphan Drug Suit
• 3rd Circ. Lipitor Ruling Smooths Way In Pay-For-Delay Suits
• Susman Godfrey Seeks To Helm Valeant Insider Trading Suit
• Calif. High Court Affirms Taxing Powers Of Voter Initiatives
• FDA Announces Security Update For St. Jude Pacemakers
• Recent Settlements Suggest Off-Label Cases Aren't Extinct
• New Jury Clears J&J In Rembrandt Contact Lens Patent Row
• Amgen, Sandoz Battle Over High Court's Biosimilar Ruling
• FDA Warning Wire: Stem Cell Clinic Fires Back
• Atty May Need DQ In Insys Bribery Case, Feds Say
• Surgeon Says Bone Drill Loud Enough To Damage Hearing
• Feds Say Shkreli Verdict Is No Escape For Ex-Katten Atty
• 3rd Circ. Ruling Doesn't Help Intuniv Buyers, Actavis Says
• DC Circ. Backs FDA's Approval Of Abilify Maintena Rival
• Express Scripts, Others Face ERISA Suit Over EpiPen Costs
• Roche Seeks NJ High Court Review Of Accutane Expert Ruling
• Rockwell Slams Claims It's Mistreating Activist's Director
• Dr. Reddy's Hid Manufacturing Woes, Investors Say
• Hedge Fund Appeals Shareholder Tax Form Decision
• CVS Board Ignored Overbilling Scheme, Shareholder Suit Says
• How Courts Treat USPTO Subject Matter Eligibility Guidelines
• Experts Must Investigate Materials They Rely On
• Provigil Buyers Lose Cert. In Pay-For-Delay Suit
• Greenberg Traurig Forgery Case Stayed For Damages Appeal
• Herbalife Products Damaged Liver, Suit Says
• Lilly Loses Bid To Escape $20M Cialis Patent Verdict
• Consumers Seek J&J Docs In Contact Lens Antitrust MDL
• FDA Drubs Stem Cell Clinics Using Unapproved Treatments
• $235M Patent Award Spurs Teva Redo Request, GSK Fees Bid
• Medical Co. In FCA Case Looks To Dodge Retaliation Claims
• Self-Collection In E-Discovery — Risks Vs. Rewards
• Gilead Sciences Inks $11.9B Deal For Kite Pharma
• Robinson Calcagnie, Smith Law Team Up To Take Down J&J
• FCA Decision Tracker: Continued Interpretations Of Escobar
• RoxyBond Rival Can't Use Suit To Delay Sales, FDA Says
• Trustee Must Face Claims In Genaera Class Action: 3rd Circ.
• Real Estate Rumors: Brookfield, MDN, Brandywine
• Fed. Circ. Affirms PTAB Nix Of Shoulder Implant Patent
• 10th Circ. Affirms Toss Of Faulty Surgical Mesh Claims
• Health Hires: Biopharma GCs, BigLaw Partners, US Prosecutor
• Examining FDA Reauthorization Act Add-On Provisions
• NYC Pharmacist Charged With Medicaid Fraud
• Foreign Discovery Mostly Denied In Zofran Birth Defect MDL
• 6 Common Lateral Partner Myths Debunked
• Del. ANDA Venue Fights Arise After TC Heartland
• 7th Circ. Says Rejected Deal Doesn't Moot False Ad Suit
• BioScrip Investors Urge Del. Justices To Revive Lawsuit
• Pharmaceutical Co. Urges 1st Circ. To Uphold PCB Suit Toss
• St. Jude Must Face Man's Defective Defibrillator Wire Suit
• Cherokee Nation Wants Takeda Actos Suit To Stay In La.
• Impax Can't Bar Goodwin Procter In Teva Coverage Fight
• Roche Appeals Accutane Label Ruling To NJ High Court
• 4 Ways Law Firms Can Help Battle Addiction
• Maine Birth Law Bars Faulty Merck Implant Suit, Judge Says
• InvaGen Infringed Diabetes Drug Patent, Pharma Cos. Say
• W. Va. Doc Gets 20 Years For Pain Prescription Abuses
• IRS Says Agent Depositions Irrelevant To CEO's Penalty Suit
• Costco, NBTY Escape Supplement Label Class Action
• ITT Wins Coverage In Asbestos Insurance Trial
• Fresenius Seeks To Shed 10 More Suits From Dialysis MDL
• Globus Defeats Securities Class Action At 3rd Circ.
• Consumers Ask 2nd Circ. To Revive 'Organic' Baby Food Suit
• Sex-Drug Sellers Settle False Ad Row Over 'Natural' Pills
• A Law Firm Guide To Helping Victims Of Human Trafficking
• Mallinckrodt Defends Hormone Price Hike In Antitrust Suit
• Alere Escapes Most, But Not All, Of Securities Class Action
• Fed. Circ. Resurrects Hindsight Bias In Post-KSR World
• 3 Trial Losses Won't Doom Xarelto Patients
• Discovery Proportionality: A Defense View
• Science No Salve For J&J In Talc Cases, $417M Verdict Shows
• US Bioservices To Settle Kickback Claims For $13.4M
• 'Open Season' For FCA Plaintiffs In 9th Circ., Gilead Says
• Feds Fight To Retry CEO Who Allegedly Gave Info To Ex-MLBer
• FTC, Boehringer Take Last Swipes In Docs Request Appeal
• Generics Makers Beat Reckitt's Mucinex Infringement Claims
• Call Center Worker Hits Drugmaker With OT Class Action
• FDA Warning Wire: Becton Dickinson, Ice Pops, Potent Drugs
• Assessing 'The Value Of Class Actions'
• PTAB Upholds AstraZeneca Diabetes Meds Patent
• 1st Circ. Affirms Dismissal Of Sarepta Securities Suit
• TTAB Says 'Medical Extrusion Technologies' Not Distinctive
• AbbVie, Patient Both Say Jury On Their Side In $150M Award
• EU Watchdog Launches Probe Of $66B Bayer-Monsanto Deal
• Calif. Court OKs Bid For Chinese Co.'s US Assets
• Del. Court Denies Toss Of Tyrogenex Takeover Plot Suit
• Feds Net $12M From Eye Surgery Co. In FCA Kickbacks Deal
• J&J Unit Seeks To Boot Pelvic Mesh Cases From Philly Court
• Krystal Biotech Files $35M IPO Led By Morrison & Foerster
• UHC Ignoring Subpoena In Testosterone MDL, Endo Says
• Pharmacy Seeks Final OK For Roche's $17M TCPA Deal
• Helsinn Redo Request Is Important Opportunity For Fed. Circ.
• Impax Loses Fees Bid In Opioid Pay-For-Delay Row With FTC
• Ex-Katten Atty Says Shkreli Verdict Nixes Conspiracy Count
• Diversity In The Legal Profession — A Stubborn Vision
• Why Midsize Firms Run The Gamut On Diversity
• Law Firms Head Back To School For Diversity Guidance
• GCs Find New Urgency In Longtime Push For Diversity
• Warner Chilcott Must Face Loestrin Pay-For-Delay MDL
• A New Standard For Suspicious Order Monitoring: Part 1
• Pa. Judge Questions Goodwin Procter DQ Bid In Pharma Fight
• 3rd Circ. Revives Lipitor, Effexor Antitrust Claims
• FDA Plans Forum On Opioid Cough Medicines For Children
• Envigo Strikes Latest Deal With A PE-Backed Acquisition Co.
• New Salary History Laws Crimp Attorney Hiring Process
• Son's Wrongful Death Case Not Federal, 11th Circ. Says
• State And Local Tax Scoreboard: 2017 Midyear Review
• Ex-BioChemics CEO's SEC Deal Bars Him From Leading Cos.
• J&J Hit With $417M Verdict In 1st Calif. Talc Cancer Trial
• Endo Misrepresented Opioid Drug Safety, Shareholder Says
• The Best Firms For Minority Attorneys
• Racial Diversity Stagnating At US Law Firms
• How 5 Firms Are Building More Diverse Ranks
• The Top Firms For Minority Equity Partners
• Class Attys Score $44.6M In Fees In $210M Salix Settlement
• Convicted Lawyer Tells High Court Gov't Let Witnesses Lie
• Jury Hands J&J, Bayer Win In 3rd Xarelto Bellwether
• Ex-ArthroCare CEO Convicted Again In $750M Fraud Scheme
• 9th Circ. Partially Revives Securities Suit Against Atossa
• Genentech Beats IP Suit Over Breast Cancer Drug Patent
• Surgery Supply Cos. Slam Bid For Cert in Antitrust Suit
• Apotex Can't Join Nearly Done Orphan Drug Suit, Eagle Says
• Reluctant Judge Approves SEC No-Fault Settlement
• J&J Unit Looks To Block Damages After Pelvic Mesh Win
• Pot Grower Tells Justices 5th Amendment Lets Him Duck Tax
• Enzo DNA Testing Patent Found Invalid In Win For Abbott
• Par Pharmaceutical Beats FCA Prescription-Switch Claims
• Stada Investors OK Sweetened €4.12B Bain, Cinven Buyout
• It's Time For Deal Talks, Attys In Zimmer Knee MDL Told
• FDA Invites Input As Pharma-Ad Overhaul Looms
• US Reps. Probe Bayer, Teva, Novartis On MS Drug Pricing
• Ex-Citigroup Analyst Defeats FINRA Charges Over Tips
• Drugmaker Moves To Stop Natal Vitamin Reclassification
• 5 Tips For A Successful Legal Blog
• Feds Urge Nix Of Ex-Hunton Atty's New Trial, Acquittal Bids
• Grammar May Send AbbVie-Novartis IP Row To Arbitration
• Xarelto Patient Says Jury Can Decide Claims
• Patheon Gets $18.5M Fees After Prevailing In Antitrust Row
• Mylan, Pfizer Escape Suit Over EpiPen Pricing
• Axed 'Short And Smear' Case Shifts To Del. Commercial Court
• Former FTC Litigator Joins Constantine's Antitrust Practice
• Opioid Distributors Facing 10 New Suits In Ala., Ohio
• Wellbutrin Buyers Didn't Show Harm By GSK, 3rd Circ. Says
• FibroGen Prices $326M Follow-On To Fund Cancer Drug
• 'Unhinged' Insider Trading Defendant Pesters Feds Again
• J&J Asks 2nd Circ. To Nix Cert. In 'Natural' Baby Wash Row
• Lateral Surge On The Horizon As BigLaw Gets Into Pot
• Sanofi Blew Whistle On Mylan's EpiPen Rebate Woes: Feds
• Opioid Litigation: What's On The Horizon
• J&J, Woman Spar Over Science At Cancer Trial's Close
• 10th Circ. Ruling Backs Tribal Court In Opioid Suit: Cherokees
• Chinese Co. Must Turn Over US Assets, Calif. Court Hears
• Minn. Justices Say Medtronic Investors Can Sue Over Merger
• Ex-US Atty Joins King & Spalding To Start Chicago Office
• Materia May Be Infringing After $1.5M Verdict, Evonik Says
• Deals Rumor Mill: Teva, Petrobras, Thyssenkrupp
• Judging A Book: Kopf Reviews Posner's 'Federal Judiciary'
• The Proper Measure Of The Value Of Class Actions
• TWi Infringed Supernus Patents For Seizure Drug, Court Says
• The 10 Law Firms Clients Recommend Most
• 3rd Circ. Divides Stryker Poaching Suit Between Calif., NJ
• Investors Seek To Strike Part Of Pershing's Quick Win Bid
• FDA Warning Wire: Another Co. Blasted For Belladonna
• Talc-Cancer Link Is Weak, J&J Expert Says At Trial's End
• Judge Rejects Theranos Investors' Bid To Pause Settlements
• Perrigo Sues IRS For $163M From Drug Sales, Patent Rows
• Judge Denies Consumers Cert. In Celexa, Lexapro MDL
• Ambry Genetics Investors Seek To Block $1B Sale To Konica
• DC Circ. Clears DEA To Block Supplier From Selling Opioids
• Par Pharma Claims Ex-Employees' New Co. Stole Secrets
• Settlement In Place For Herbal Supplement MDL Cases
• Generic Lobby Can't Block Drug Price-Gouging Law, Md. Says
• AFL-CIO Heads Latest To Leave Trump's Job Panel
• The Use Of Special Masters In Complex Cases
• A Plaintiff's Guide To Discovery Proportionality: Part 2
• Notes From A Law Firm Chief Privacy Officer
• No Sign J&J Talc Caused Woman's Cancer, Doc Tells Jury
• Talk Of Deal As Women Ask 2nd Circ. To Revive Mirena MDL
• J&J, Bayer Ask To Strike Doc's Testimony In Xarelto Trial
• IP Trade Association Pushes USTR To Adopt NAFTA Priorities
• Chinese Pharma Co. Gets Nasdaq Leeway Amid FCPA Probe
• CVS, Walgreens Press Bid To Block Cherokee Opioid Suit
• Pa. Judge Explains Call To Keep $2.5M J&J Risperdal Verdict
• FDA's Hatch-Waxman Group To Tackle Wider Generics Issues
• No Cracks In Antitrust Suit Against Biogen, Rival Argues
• A Plaintiff's Guide To Discovery Proportionality: Part 1
• Intel CEO Joins Execs Fleeing Trump Council After Protests
• Notes From A Law Firm Chief Privacy Officer: New Demands
• Del. Case May Set New Roadblocks For 3rd-Party Releases
• Grant & Eisenhofer Claims $7M In Fees Owed From FCA Deal
• Greatbatch-AVX Trial's Willfulness Stage Ends In Hung Jury
• News Outlets Ask Shkreli Trial Judge For Juror Names
• Talc No Cancer Risk, Ex-FDA Scientist Tells J&J Jury
• DaVita Investors Move To Consolidate Derivative Suits
• Mylan Can't Duck Securities Fraud Suit, Investors Say
• Health Hires: CMS Officials Move On To BCBS, PatientPing
• Brand Battles: Uber, Novartis, Coachella, General Motors
• Medical Device Cos. Must Arbitrate IP Dispute, Judge Says
• Escobar Provides New Grounds For Seeking Gov't Discovery
• BioScrip Urges Del. Justices Not To Revive Shareholder Suit
• Fed. Circ. Pushed To Revive $200M Boston Scientific IP Suit
• Thermo Fisher Raises $1.5B Debt To Fund Patheon Acquisition
• What To Know About New FDA Informed Consent Guidance
• It's Time To Improve Voir Dire In Federal Court
• Notes From A Law Firm Chief Privacy Officer: Insider Risks
• Acorda Asks Fed. Circ. To Undo Nix Of Ampyra Drug Patents
• Woman Says Cancer A Surprise After Years Of J&J Talc Use
• Fed. Circ. OKs $12M Fees For Lilly, Elan In IP 'Conspiracy'
• Del. Jury Finds AVX Infringed Greatbatch Device Patent
• Trump To Declare Opioid Crisis A National Emergency
• SEC Fights Broker's Bid To Slip $1.6M Sanofi Fraud Verdict
• Allergan Again Pressures FDA On Restasis Generics
• FDA Says Fla. Pharmacy Is Not Properly Sterilizing Equipment
• Shook Hardy Nabs Life Sciences Trial Pro From Hollingsworth
• AIG, Liberty Say They Don't Have To Cover $11M LabCorp Deal
• Fed. Circ. Snubs Amgen Bid For More Info On Pfizer Biosimilar
• Rising Star: Quinn Emanuel's Laura Fairneny
• 5 Deaths Linked To Obesity Stomach Balloons, FDA Warns
• Notes From A Law Firm Chief Privacy Officer: Balancing Act
• NH, Ore. County Accuse Opioid Makers Of Fueling Crisis
• Shire Beats Contract Suit Seeking $425M From Dry-Eye Drug
• FCPA Prosecutor Returning To Foley & Lardner In DC
• Trade Secrets Victor Had No Part In Tech, Fed. Circ. Told
• What Attys Need To Know About Trump's Opioid Policies
• Mesh Ruling Signals Tough Road For Non-Pa. Cases In Philly
• Humana Beats NJ Specialty Pharmacy's Antitrust Suit
• Dechert Guides Zealand Pharma's Upsized $78M IPO
• ITC Will Probe Hemophilia B Med Patent Infringement Claims
• 3rd Circ. Affirms Win For GSK In Wellbutrin Antitrust Case
• SoftBank Fund Leads $1.1B Equity Investment For Roivant
• Rising Star: Gibson Dunn's Timothy Best
• Deals Rumor Mill: Altice, Teva Pharmaceuticals, Fanatics
• Abuse-Deterrent Opioids Unproven, Unaffordable, Study Says
• Vitamin Shoppe Sued Over Weight Loss Supplement
• Locke Lord Gains London Partner With IP Finesse
• UK Supreme Court Broadens Scope Of Patent Protection
• How The IPad Can Be A Litigator's Best Friend
• Notes From A Law Firm Chief Privacy Officer: CPO Vs. CISO
• Studies Showing No Talc-Cancer Link Are Flawed, Jury Hears
• Athena Diagnostic Test Patent Axed For Covering Natural Law
• Monsanto Reaches Nationwide Roundup False Ad Deal
• Generic Giants Ask Fed. Circ. To Nix Vimpat Patent
• FDA Warning Wire: NYC Embryo Co., Feline Peanut Protector
• Price Hike Not Shkreli's Only Antitrust Woe, Experts Argue
• 9th Circ. Decision Could Be A Bitter Pill For Pharma Cos.
• Mintz Levin Nabs Perkins Coie Patent Atty For NY Office
• Novo Nordisk, Benefits Co. Want Price Hike Fight Sent To NJ
• Rising Star: Hogan Lovells' Adam Bellack
• Apotex Wants In On Orphan Drug Suit To Protect Generic
• Damaged Drug Claims Unsupported, CVS Unit Says
• Pacemaker Co. Wins CIT Suit Over Import Classification
• Industrial Talc Litigation: New Mass Tort Or False Alarm?
• The Rule Of Law Is The Best Medicine: Part 2
• 5 Questions To Ask Before Entering Joint-Representation AFA
• Quinn Emanuel Says Pharma Co. Owes $6M In Back Fees
• Greatbatch, AVX Duel Over Proof And 'Illusion' In IP Trial
• Shkreli's Brazen Defiance May Lead To Harsher Sentence
• Merck Tells Fed. Circ. Antibiotic Obvious Only In 'Hindsight'
• Endo To Pay $775M To End 'Virtually All Known' Mesh Suits
• Fla. Doctor Gets 6 Years For Using Foreign, Unlicensed Drugs
• Monsanto Can Pause Cities' PCBs Suit, Judge Rules
• New FDA Study Supports Simpler Pharma Ads
• Coherus Targets Amgen's Enbrel Patent In IPR
• FDA Says Death Linked To Turmeric IV Product
• K&L Gates Hires Former Sen. Murkowski Staffer As Partner
• FDA Ignoring Abuse-Deterrent Opioid Concerns, Suit Says
• Acorda Therapeutics Slams Investor's Calls To Explore Sale
• Rising Star: Kirkland's Elizabeth Hess
• Fresenius To Buy Home Dialysis Firm NxStage For $2B
• Legal Incubators Can Help New Lawyers And Society
• Metal Fragments In Brain Isn't Injury, 11th Circ. Rules
• BASF Can't Nix NJ Town's Expert In Superfund Site Tax Row
• The Rule Of Law Is The Best Medicine: Part 1
• Talc Use Causes Ovarian Cancer, Calif. Jury Told
• FDA Blocks Utah Outsourcing Co. That Sold Tainted Drugs
• Latest J&J Pelvic Mesh Injury Case Kicks Off In Philly
• Cempra Shareholder Sues Over CEO's Retirement Package
• Miramar Labs Investor Challenges Sientra Deal
• Ultrasound Co. Says Its Arbitral Award Nearly Doubled
• 3 Firms Set To Steer IPOs Totaling $310M Led By Coal Miner
• Taxation With Representation: Debevoise, Weil, Davis, Hogan
• Other Jurisdictions Should Look To 9th Circ.'s Teleflex Ruling
• Rising Star: Axinn Veltrop's Suchira Ghosh
• Shkreli Convicted On 3 Counts In Securities Fraud Trial
• Hedge Funds Sue Teva Over Generic Drug Price-Fixing
• No-Show NYC Pharmacy Loses TCPA Junk Fax Class Action
• A Modern Approach To Digital Health Product Regulation
• The Growing Circuit Split Over FCA First-To-File Rule
• What To Watch As FDA Begins To Fight Rising Drug Prices
• Breaking Down Graham-Cassidy ACA-Replacement Proposal
• PE Firm Wins $87M In Contaminated Heparin Coverage Suit
• Genentech Says IP Suit Should End After Phigenix Attys Leave
• Hurdles Ahead For AbbVie After $150M AndroGel Verdict
• JPML Sends Acid-Reflux Drug Litigation To New Jersey
• Express Scripts Can't Dodge PE Firm's Fraud Suit
• Medical Supplier Wants Abbott Sanctions In Test Strip Suit
• Congress Passes FDA Reauthorization, Approval Reforms
• Israeli Pharma Co. Wants NY Stock-Drop Class Suit Tossed
• Bristol-Myers Squibb: The Aftermath
• Philips Nets Just $7.1M In Defibrillator Infringement Case
• Pa. Court Asked To Revive Actiq Off-Label Marketing Suit
• Troutman Sanders Taps King & Spalding For Atlanta Partner
• 2nd Circ. Affirms Icahn Win Over Short-Swing Trading Suit
• How To Prioritize Your Law Firm's Crisis Response Plan
• Patent Prosecutors Alarmed By Inequitable Conduct Ruling
• Roche May Test Liberal NJ Expert Standard In Accutane Battle
• J&J, DePuy Fight Hip Implant Claims Ahead Of 4th Bellwether
• Ex-Harvard Doc Tells Jury Woman's Ovaries Contained Talc
• Perrigo Gets A Mulligan On $10M IP Verdict Appeal
• Boehringer Biosimilar Flouts 74 Patents, AbbVie Says
• Minn. Justices Nix $1.2M Tax Bill Over Foreign Entity Status
• Texas Court Tosses Suit Over Newborn's Genetic Test
• Ecolab Reaches $6M Wage Settlement With Sales Managers
• Merck Investors' Claims Time-Barred, 3rd Circ. Finds
• Pa. Judge Will Revisit Out-Of-State Cases In Mesh Mass Tort
• DOJ Ramps Up Fight Against Opioid Fraud With 12-Atty Unit
• Judge Tosses Fraud Claims In $2.3B Teva Acquisition Suit
• Fed. Circ. Affirms Axing $61M DNA Patent Win For Yale, Enzo
• Clementia Pharmaceuticals Raises $120M In Upsized IPO
• Oilfield Services Co., Drugmaker Launch IPOs Totaling $160M
• Another Instant Coffee Recalled For Containing Viagra
• KKR, Walgreens Take PharMerica Private In $1.4B Deal
• Zimmer Says Expert Reports Lacking In 95 Knee MDL Cases
• Trimming An MDL Expert's Testimony On Remand
• A Glimpse Into DOJ's New Health Care Enforcement Initiative
• Has Amgen Already Won Its BPCIA Dispute With Sandoz?
• Innovating For Wise Juries: Closing Argument
• Reed Smith Atty's Doctor Knew Of Suicide Risk, GSK Says
• Pharma Co. Won't Get More Time To Keep SEC Registration
• Theranos, Walgreens Settle $140M Contract Suit
• Express Scripts Ducks Stockholder Suit Over Anthem Dispute
• Cleveland Clinic Wants Rehearing Of Heart Test Patent Ax
• Shkreli Jury Asks Judge About 'Fraudulent Intent'
• FTC Shouldn't See Aggrenox Docs, Boehringer Tells DC Circ.
• Express Scripts Will Favor Mylan's EpiPen Over Competitors
• Jefferies Dodges Arbitration With Biotech Investors
• Genetic Medicine Co. Raises $83.5M For Drug Development
• Patent Co. Asks Fed. Circ. To Revive Hip Implant Patent
• Bayer, Monsanto Offer EU Concessions To Clear $66B Deal
• Insurer Fights Covering Negligence Claims In Med Mal Suit
• Medical Co. Owner Charged With Diverting Investor Funds
• An FDA Petition Denial Preempts A Failure-To-Warn Claim
• What's Next For ACA Repeal?
• Daiichi, Forest Reach $300M Settlement In Benicar MDL
• 5 Questions All AFAs Should Answer Clearly